… VSL#3 are derived from in vitro studies and animal models, and further study is warranted into
the immune responses associated with VSL… response following oral treatment with VSL#3. …

… of VSL#3 in chronic diseases of animals and humans (including children). We found that
VSL#… This review seeks to provide an overview of the role of VSL#3 in various kinds of diseases …

Aim : To investigate the effects of a probiotic formulation, VSL#3, on gastrointestinal transit
and symptoms of patients with Rome II irritable bowel syndrome with predominant diarrhoea. …

… All 3 patients treated with VSL# 3 and 6 of 11 (54.5%) patients … VSL# 3 group than in the
placebo group (P< 0.05). There were no biochemical or clinical adverse events related to VSL# 3…

Background & Aims Probiotic formulations of single species of bacteria have not been effective
in preventing the recurrence of Crohn’s disease after surgery. We investigated the ability …

… Thirty-two patients completed 6 wk of VSL# 3 treatment and 2 patients did not have the final
… clinical adverse events related to VSL# 3. Two of the components of VSL# 3 were detected …

Objectives: To evaluate whether chronic therapy with probiotics affects plasma levels of
cytokines and oxidative/nitrosative stress parameters, as well as liver damage, in patients with …

… types and provide a range of VSL estimates to use in sensitivity analyses. … VSL pay grade
and income adjustments to US military fatalities in Afghanistan and Iraq, we find adjusted VSL …

… , double‐blind design to placebo or VSL# 3 twice daily (31 patients received … VSL# 3 was
associated with reduced flatulence over the entire treatment period (placebo 39.5 ± 2.6 vs VSL…

… VSL#3 seems more safer than fecal microbiota transplantation, because serious adverse
events were not reported in the VSL… and that of mixed probiotics VSL#3. However, the use of …